Seelos Therapeutics alternatives

Johnson & Johnson’s Spravato (esketamine) nasal spray is the most direct commercial comparator, already approved for depression with different dosing and REMS requirements. Other developers are testing racemic ketamine or analogs in nasal or oral forms but remain earlier stage.

Biogen, Amylyx, and Mitsubishi Tanabe have approved or late-stage ALS assets. Seelos differentiates via trehalose autophagy enhancement in the HEALEY platform, while competitors rely on neuroprotection, glutamate modulation, or gene silencing.

Sage concentrates on GABA and NMDA modulators for depression and neurology with multiple approved or near-approved drugs. Seelos maintains a wider but earlier-stage mix including gene therapy and autophagy assets across both psychiatry and rare neurodegenerative diseases.

Voyager Therapeutics and uniQure pursue CNS gene therapies, primarily for Parkinson’s or Huntington’s. Seelos SLS-004 remains undisclosed in detail, making direct comparison difficult until target and vector data emerge.

Approved CNS drugs from larger firms follow specialty-pharmacy or buy-and-bill models with REMS programs. Smaller developers like Seelos have no commercial products yet, so pricing remains unknown until approval.

Few direct autophagy modulators are in clinical development for neurodegeneration. Competitors more commonly target protein clearance via antisense, antibodies, or proteasome pathways, leaving Seelos mechanism relatively novel.